IV infusion of casirivimab and imdevimab authorized for treatment of mild-to-moderate COVID-19
FDA Issues EUA to Baricitinib Plus Remdesivir for COVID-19
Emergency use authorization applies to hospitalized patients requiring supplemental oxygen, mechanical ventilation, ECMO